Governing the AI–biotech convergence: The rapid progress in and the dual-use nature of biotechnology and AI requires adaptive and resilient regulatory frameworks to address potential risks
Benjamin D Trump, Christopher L Cummings, Beth Ellinport, Stephanie Galaitsi, Thomas Janisko, Elizaveta Pinigina, Hannah Herzig, Cindy S Groff-Vindman, Markus Schmidt, Gerald Epstein, Ruth Mampuys, Christian Haggenmiller, Tatyana Novossiolova, Travis Tubbs, James H Lambert

TL;DR
This paper discusses the need for strong regulations to manage the risks of combining AI and biotechnology.
Contribution
The paper emphasizes the need for adaptive governance frameworks to address ethical and security risks in AI-biotech convergence.
Findings
AI and biotechnology convergence brings ethical and security risks.
Adaptive governance is needed to manage these risks responsibly.
Abstract
The convergence of artificial intelligence with biotechnology accelerates innovation but also introduces significant ethical and security risks. These require adaptive, flexible governance strategies that ensure that breakthroughs can be managed responsibly while mitigating potential risks.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLaw, AI, and Intellectual Property · Neuroethics, Human Enhancement, Biomedical Innovations · Ethics and Social Impacts of AI
